Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Experimental Hematology & Oncology

Correspondence

Xubo Gong¹  Lan Jin¹  Zhihua Tao¹  Huiying Xu¹  Lin Wang¹  Weiwei Liu¹  Milad Moloudizargari²  Xin He²  Yi Zhang³  Yang Xu⁴  Wenbin Qian⁴  Teng Yu⁴ 

[1] Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, 310000, Hangzhou, Zheijang, P.R. China;Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, USA;Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003, Hangzhou, Zheijang, P.R. China;Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, 310009, Hangzhou, P.R. China;

关键词: Venetoclax;    Acute myeloid leukemia;    Hypomethylating agents;   

DOI  :  10.1186/s40164-023-00424-z

 received in 2023-05-04, accepted in 2023-06-23,  发布年份 2023

来源: Springer

【 摘 要 】

Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment.

【 授权许可】

CC BY   
© The Author(s) 2023